tbuckley/cabot-search huggingface dataset:
MA11.04 First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study
Authors: J. Zhou, N. Xu, J. Shan, Y. Wang, W. Fang, H. Wang, Y. Pan, Y. Chen, X. Liang, Q. Chu, J. Cui, Y. Sun, J. Fang, X. Liu, N. Li, S. Long, Y. Chen, L. Zhao, H. Wang, T. Liang
Journal: Journal of Thoracic Oncology (2024)
MA12.10 Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial
Authors: F. Opdam, J.V. Heymach, D. Berz, M. Barve, H.-Y. Tu, Y.-L. Wu, L. Schroeter, J. Serra, B. Sadrolhefazi, K. Yoh, N. Yamamoto
Journal: Journal of Thoracic Oncology (2024)
MA11.12 A Phase Ib Study of TQB2618 (Anti-TIM-3) in Combination with Penpulimab and Chemotherapy in Patients with Non-Small Cell Lung Cancer
Authors: L. Wu, G. Lin, B. Li, Y. Fang, Y. Wang, S. Cang, X. Li, X. Li, R. Wang, Q. Chu, Q. Yu, R. Ning, Z. Gui, Z. Zhou
Journal: Journal of Thoracic Oncology (2024)
MA13.12 Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes in Selected Lung Adenocarcinoma Patients
Authors: O. Arrieta, E. Caballé-Pérez, N. Hernández-Pedro, E. Romero-Nuñez, J. Lucio-Lozada, C. Castillo-Ruiz, K. Acevedo-Castillo, R.M. Álvarez-Gómez, C. Molina-Garay, M. Jiménez-Olivares, K. Carrillo-Sánchez, E.C. Mendoza-Caamal, A.F. Cardona, J. Remon, C. Alaez-Verson
Journal: Journal of Thoracic Oncology (2024)
MA11.08 Preliminary Efficacy and Safety of SHR-1701 Plus Fluzoparib as Maintenance Therapy for Patients with Advanced Lung Squamous Cell Carcinoma
Authors: Y. Zhang, L. Zeng, W. Jiang, L. Liu, Y. Xiong, L. Tian, C. Zhao, N. Yang
Journal: Journal of Thoracic Oncology (2024)
MA10.04 The Financial Toxicity of Lung Cancer Impacts All Spheres of Life
Authors: D. Villalón, A. Aguarón, M. O’Sullivan, E. Pataki, A. Hans, D. Montague, L. Magee, M. Forsblom, E. Szmytke, A.-M. Baird
Journal: Journal of Thoracic Oncology (2024)
MA10.03 Paying the Price: How Lung Cancer Care Impacts Wallets and Well-Being
Authors: D.L. Pottinger, S. Olisakwe, C. Williams, Q. Hussaini, Y. Boumber, U.B. Roy, J. Feldman, G. Rocque, M. Khalil, A. Desai
Journal: Journal of Thoracic Oncology (2024)
MA09.06 Use of Biosimulation to Predict Chemotherapy Benefit in Patients with Metastatic NSCLC Being Treated with Immunotherapy
Authors: M. Klein, D. Watson, S. Kapoor, P.R. Nair, S. Rajagopalan, M. Glaser, N. Sharif, M. Stonebarger, A. Westanmo, D.A. Lala, A. Kumar, J. Chauhan, P. G, Y.S. Ullal, S. Kulkarni, A. Ghosh, Y. Narvekar, M. Patil, M. Castro, M. Macpherson, J. Wingrove, T. Patil, A. Ganti, C. Aggarwal
Journal: Journal of Thoracic Oncology (2024)
OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
Authors: E. Felip, H.A. Wakelee, E. Vallieres, A. Martinez-Marti, O. Goloborodko, C. Zhou, A. Rittmeyer, A. Chella, M. Reck, T. Csoszi, I. Bondarenko, H. Kenmotsu, W. Schutte, B. Ding, Q. Zhu, M. Ballinger, E. Bennett, B.J. Gitlitz, N. Altorki
Journal: Journal of Thoracic Oncology (2024)
PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2
Authors: C. Zhou, J. Chen, L. Wu, L. Wang, B. Liu, J. Yao, H. Zhong, J. Li, Y. Cheng, Y. Sun, H. Ge, Q. Shi, M. Zhou, Z. Han, J. Wang, Q. Bu, Y. Zhao, J. Chen, J. Yang, M. Xia
Journal: Journal of Thoracic Oncology (2024)
PL04.03 Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study
Authors: X. Le, N. Girard, P.A. Jänne, S. Novello, H.R. Kim, H.H. Loong, B.C. Goh, K.H. Lee, K. Nishino, S. Lu, X. Dong, J. Zhao, T.A. Leal, D.S.-W. Tan, K. Goto, T. Descamps, B.J. Brennan, R. Li, P. Grassi, T.M. Kim
Journal: Journal of Thoracic Oncology (2024)
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up
Authors: K. Cuppens, P. Baas, M. Wiesweg, B. Du Pont, T. Ploenes, D. Theegarten, C. Aigner, K. Hartemink, B. Maes, K. Pat, M. Schuler
Journal: Journal of Thoracic Oncology (2024)
OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
Authors: D.R. Jones, H. Wakelee, J.D. Spicer, M. Liberman, T. Kato, M. Tsuboi, S.-H. Lee, W. Wang, H. Chen, C. Dooms, M. Majem, E. Eigendorff, G.L. Martinengo, O. Bylicki, H.-C. Huang, S. Novello, E. Jensen, S.M. Keller, A. Samkari, N. Kalhor
Journal: Journal of Thoracic Oncology (2024)
FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine
Authors: Haider J. Warraich, Troy Tazbaz, Robert M. Califf
Journal: JAMA (2024)

Importance Advances in artificial intelligence (AI) must be matched by efforts to better understand and evaluate how AI performs across health care and biomedicine as well as develop appropriate regulatory frameworks. This Special Communication reviews the history of the US Food and Drug Administration’s (FDA) regulation of AI; presents potential uses of AI in medical product development, clinical research, and clinical care; and presents concepts that merit consideration as the regulatory system adapts to AI’s unique challenges. Observations The FDA has authorized almost 1000 AI-enabled medical devices and has received hundreds of regulatory submissions for drugs that used AI in their discovery and development. Health AI regulation needs to be coordinated across all regulated industries, the US government, and with international organizations. Regulators will need to advance flexible mechanisms to keep up with the pace of change in AI across biomedicine and health care. Sponsors need to be transparent about and regulators need proficiency in evaluating the use of AI in premarket development. A life cycle management approach incorporating recurrent local postmarket performance monitoring should be central to health AI development. Special mechanisms to evaluate large language models and their uses are needed. Approaches are necessary to balance the needs of the entire spectrum of health ecosystem interests, from large firms to start-ups. The evaluation and regulatory system will need to focus on patient health outcomes to balance the use of AI for financial optimization for developers, payers, and health systems. Conclusions and Relevance Strong oversight by the FDA protects the long-term success of industries by focusing on evaluation to advance regulated technologies that improve health. The FDA will continue to play a central role in ensuring safe, effective, and trustworthy AI tools to improve the lives of patients and clinicians alike. However, all involved entities will need to attend to AI with the rigor this transformative technology merits.
Testing and Evaluation of Health Care Applications of Large Language Models
Authors: Suhana Bedi, Yutong Liu, Lucy Orr-Ewing, Dev Dash, Sanmi Koyejo, Alison Callahan, Jason A. Fries, Michael Wornow, Akshay Swaminathan, Lisa Soleymani Lehmann, Hyo Jung Hong, Mehr Kashyap, Akash R. Chaurasia, Nirav R. Shah, Karandeep Singh, Troy Tazbaz, Arnold Milstein, Michael A. Pfeffer, Nigam H. Shah
Journal: JAMA (2024)

Importance Large language models (LLMs) can assist in various health care activities, but current evaluation approaches may not adequately identify the most useful application areas. Objective To summarize existing evaluations of LLMs in health care in terms of 5 components: (1) evaluation data type, (2) health care task, (3) natural language processing (NLP) and natural language understanding (NLU) tasks, (4) dimension of evaluation, and (5) medical specialty. Data Sources A systematic search of PubMed and Web of Science was performed for studies published between January 1, 2022, and February 19, 2024. Study Selection Studies evaluating 1 or more LLMs in health care. Data Extraction and Synthesis Three independent reviewers categorized studies via keyword searches based on the data used, the health care tasks, the NLP and NLU tasks, the dimensions of evaluation, and the medical specialty. Results Of 519 studies reviewed, published between January 1, 2022, and February 19, 2024, only 5% used real patient care data for LLM evaluation. The most common health care tasks were assessing medical knowledge such as answering medical licensing examination questions (44.5%) and making diagnoses (19.5%). Administrative tasks such as assigning billing codes (0.2%) and writing prescriptions (0.2%) were less studied. For NLP and NLU tasks, most studies focused on question answering (84.2%), while tasks such as summarization (8.9%) and conversational dialogue (3.3%) were infrequent. Almost all studies (95.4%) used accuracy as the primary dimension of evaluation; fairness, bias, and toxicity (15.8%), deployment considerations (4.6%), and calibration and uncertainty (1.2%) were infrequently measured. Finally, in terms of medical specialty area, most studies were in generic health care applications (25.6%), internal medicine (16.4%), surgery (11.4%), and ophthalmology (6.9%), with nuclear medicine (0.6%), physical medicine (0.4%), and medical genetics (0.2%) being the least represented. Conclusions and Relevance Existing evaluations of LLMs mostly focus on accuracy of question answering for medical examinations, without consideration of real patient care data. Dimensions such as fairness, bias, and toxicity and deployment considerations received limited attention. Future evaluations should adopt standardized applications and metrics, use clinical data, and broaden focus to include a wider range of tasks and specialties.
P4.04C.01 Incidental Pulmonary Nodule Management Using Computer Assisted Detection and Patient Tracking: PINPOINT Project, Pilot Data
Authors: A. Leliveld, B. Willems, E.J.R. van Beek, L. Gorospe, A. Veltri, J.J. Visser, G.V. Scagliotti, J.G.J.V. Aerts
Journal: Journal of Thoracic Oncology (2024)
P4.04D.02 Lung Cancer in Never Smokers and Individuals with a Family History of Lung Cancer: Missed Opportunities for Screening
Authors: R. Yip, T. Holton, J. Zhang, H. Chan, S. Kantor, J. Zhu, S. Woode, L. Lentini, D.F. Yankelevitz, C.I. Henschke
Journal: Journal of Thoracic Oncology (2024)
P4.04D.07 Lung Cancer Biomarkers in Nonsmokers: Diagnostic and Prognostic Use of Liquid Biopsy for Metabolites Found in the Urine
Authors: B. Dalal, T. Tada, D.P. Patel, S.R. Pine, M. Khan, T. Oike, Y. Kanke, A.L. Parker, M. Haznadar, L. Toulabi, K.W. Krausz, A.I. Robles, E.D. Bowman, F.J. Gonzalez, C.C. Harris
Journal: Journal of Thoracic Oncology (2024)
P4.07D.03 Phase 2 Peri-Operative Study of Fianlimab+Cemiplimab+Chemotherapy vs Cemiplimab+Chemotherapy in Resectable Early-Stage NSCLC
Authors: L. Paz-Ares, N. Girard, A. Spira, U. Chaudhry, M. Ghattas, S. Li, M. Salvati, I. Lowy, M.G. Fury, L. Paoluzzi
Journal: Journal of Thoracic Oncology (2024)
P4.07E.03 Real-World Data on Early Lung Cancer in Never-Smokers and Light Smokers-Prevalence, Family History, and Molecular Alterations
Authors: L. Gros, R. Yip, H. Chan, J. Zhu, S. Kantor, D.F. Yankelevitz, C.I. Henschke
Journal: Journal of Thoracic Oncology (2024)
P4.04D.04 Efficiency of the Annual CT Screening Interval for Those at a Lower Risk of Lung Cancer - A CISNET Comparative Modelling Study
Authors: K. de Nijs, H.J. de Koning, P. Cao, H. Mahmoudi, M. Diasporra, R. Garner, J. Jeon, E.J. Feuer, J.H.E. Yong, S. Gazelle, R. Meza, K. ten Haaf
Journal: Journal of Thoracic Oncology (2024)
P4.04C.11 Pixel-Wise Pulmonary Nodule Growth Prediction on Low-Dose Computed Tomography with 3D-ConvLSTM Deep Neural Network
Authors: H. Li, J. Jang, M. Tang, F. Zheng, B. Zhang, M. Deng, H. Chen, X. Lu
Journal: Journal of Thoracic Oncology (2024)
P4.07E.07 Spatial Memory B Cells Activation by CXCL13+ Th Cells via the MIF(CD74-CXCR4) Axis may Improve Immunotherapy Efficacy in HER2 Mutant NSCLC
Authors: H. Hong, C. Zhang, L.-X. Yan, S-y. Liu, H.-J. Li, B.-Y. Jiang, H.-Y. Tu, Y.-L. Wu, W.-Z. Zhong
Journal: Journal of Thoracic Oncology (2024)
P4.04D.01 Gender Disparities in Lung Cancer Screening: A Systematic Literature Review
Authors: E. Shum, N. Florez, J. Brahmer, C. Aggarwal, H. Wakelee, M. Chau, R. Shenolikar, R. Salomonsen, J. Chaieb, L. Luciani-Silverman, D. Guy, L. Woldmann, A.-A. Ciritel, S. Peters
Journal: Journal of Thoracic Oncology (2024)
P4.04D.06 Improving Lung Cancer Risk Prediction in Asbestos Exposed Individuals: An Ensemble Approach
Authors: C. Kumarasamy, K. Betts, R. Norman, A. McWilliams, E. Stone, D.C.-L. Lam, R. Manser, P. Fogarty, H. Marshall, S. Lam, M.C. Tammemägi, K.M. Fong, S. Atkar-Khattra, F. Brims
Journal: Journal of Thoracic Oncology (2024)
P3.12D.01 A Phase Ib Study of Osimertinib and Tegavivint as First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: R. Memmott, J. Gheeya, L. Wei, M. Phelps, W. Yang, D. Stenehjem, S. Horrigan, A. Duncan, D. Uribe, G. Amato, G. Otterson, J. Kaufman, A. Alahmadi, C. Presley, D. Owen, D. Carbone
Journal: Journal of Thoracic Oncology (2024)
P3.13D.01 Proteomic Characterization of Antibody Drug Conjugate Target Expression Profiles in Small Cell Lung Cancer (SCLC)
Authors: E. Lin, A. Khosla, N.K. Smrecek, A.R. Naqash, K. Parikh, Y. Boumber, M. Khalil, A. Desai
Journal: Journal of Thoracic Oncology (2024)
P3.12C.04 Seribantumab Results in Robust and Durable Responses in NRG1 Fusion-Positive Non-Small Cell Lung Cancer: A Multi-Center Case Series
Authors: C.E. Lau, T. Patil, V. Jansen, D.R. Carrizosa, J.D. Patel
Journal: Journal of Thoracic Oncology (2024)
P3.12E.05 Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC
Authors: M.L. Johnson, D. Younan, S. Kent, A. Balasubramanian, M. Mesa-Frias, B. Stollenwerk, B.E. Sylvester, B. Mehta, V. Chia, M.A. Brookhart, A. Spira
Journal: Journal of Thoracic Oncology (2024)
P4.04D.05 Family History is an Independent Predictor of Lung Cancer Detection in Women in a Predominantly Caucasian Screening Cohort
Authors: X. Hu, C. Rofe, K. Fong, H. Marshall, F. Brims, A. McWilliams, R. Manser, P. Fogarty, S. Lam, S. Atkar-Khattra, R. Myers, E. Silverstone, B. Milner, E. Hsu, E. Stone
Journal: Journal of Thoracic Oncology (2024)
P3.13D.06 Distinct Single-Cell Transcriptomic Characteristics and Responses to the Front-Line Therapy in Patients with Central or Peripheral ES-SCLC
Authors: L. Luo, R. Xia, S. Mao, Q. Liu, H. Du, L. Chen, F. Wu, S. Ren
Journal: Journal of Thoracic Oncology (2024)
P3.13C.02 A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving Immunotherapy
Authors: D.R. Gandara, D.P. Carbone, A.P. Dicker, P. Christopoulos, I. Puzanov, P. Jain, D. Farrugia, S. Brown, M. Moskovitz, J. Bar, A. Hassani, A. Chatterjee, M. Abu-Amna, A. Polychronis, A. Brewster, Y. Lou, N.A. VanderWalde, M. Gottfried, C. Lahav, G. Lowenthal, I. Sela, M. Harel, Y. Elon, M.A. Schneider
Journal: Journal of Thoracic Oncology (2024)
P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study
Authors: A.H. Nassar, K. Matteson, T. Adeyelu, A. Ocejo, F. Ardeshir, T. Leal, S. Ramalingam, J.E. Gray, K. Hicks, D. Kaldas, J. Baena, M. Zurera Berjaga, D.J. Kwiatkowski, F. Aboubakar Nana, C. Grohe, H. Leuders, F. Citarella, A. Cortellini, E.C. Mingo, D. Pancirer, M. Das, T. John Ellis-Caleo, J.M. Cheung, J.J. Lin, A. Watson, R. Camidge, A. Sridhar, K. Parikh, F. Crowley, T. Marron, V. Aggarwal, A. Murtaza, K. Sankar, H. Kawtharany, J. Zhang, D. Owen, M. Li, M. Nagasaka, D. Pinato, K. Alhamad, S. Puri, N. Awosika, U. Zaman, M. Evans, A. Vanderwalde, G. Lopez, h. borghaei, C. Kim, A.R. Naqash, A. Chiang
Journal: Journal of Thoracic Oncology (2024)
P3.08F.01 Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)
Authors: W.-Z. Zhong, C. Zhang, Y. Yang, J. Yang, Q. Zhou, Q. Zhong, W. Liang, Z. Chen, Y. Wu
Journal: Journal of Thoracic Oncology (2024)
P4.04C.04 Epidemiological Characteristics of Incidental Pulmonary Nodules and in China: A Prospective Multicenter Trial of 10,560 Cases
Authors: W. Liang, D. Liu, C. Hu, W. Xiao, J. Zhang, M. Peng, S. Wu, B. Wang, J. He, J.-B. Fan, N. Zhong
Journal: Journal of Thoracic Oncology (2024)
P3.13D.11 SEZ6 Expression in Neuroendocrine Tumors
Authors: J.A. Marks, K. Sweeney, A. Elliott, B. Gupta, A. VanderWalde, S. Puri, M.D. Shields, J.J. Nieva, H.P. Soares, P.C. Ma, B. Halmos, S.V. Liu
Journal: Journal of Thoracic Oncology (2024)
P4.04C.07 Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT
Authors: L. Cotton, P. Bach, E. Kazerooni, C. Cisar, D. Tennefoss, C. Schonewolf, M. Wilson, C. Magnuson
Journal: Journal of Thoracic Oncology (2024)
P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Authors: S. Gadgeel, A. Rahman, U. Osaghae, T.M. Fernando, M.T. Lin, K. Koli, C. Meyenberg, M. Mathisen, F. Skoulidis
Journal: Journal of Thoracic Oncology (2024)
P3.12C.03 Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma
Authors: N. Yamamoto, U.M. Lauer, T. Humphries, N. Natarajan, P. LoRusso, H. Prenen, J. Bartolomé, M. He, G. Jayadeva, M. Teufel, A. Märten, J. Kratz
Journal: Journal of Thoracic Oncology (2024)
P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC
Authors: A. Sacher, A. Addeo, T. Doi, Q. Chu, A. El Helali, L. Villaruz, H. Prenen, N. Vokes, J. Rodon, G. Durm, L. Lebellec, B. O’Neil, G. Dy, T. Eggert, K. Keyvanjah, S. Gadgeel
Journal: Journal of Thoracic Oncology (2024)
P3.12E.03 Anti-Tumor Efficacy of HRS-4642 and its Potential Combination with Proteasome Inhibition in KRAS G12D-Mutant Cancer
Authors: L. Luo, C. Li, K. Jia, X. Li, Z. Zhang, F. Li, C. Zhou, S. Ren
Journal: Journal of Thoracic Oncology (2024)
P3.13C.04 Assessing ctDNA using a Methylation-informed Molecular Response Algorithm in Extensive-Stage Small Cell Lung Cancer Patients
Authors: J.S. Gheeya, L. Bucheit, S.R. Solomon, A. Yablonovitch, C. Pilcher, C.J. Presley, E. Bertino, P.G. Shields, K. He, V. Sukrithan, B. Konda, C.F. Verschraegen, D. Carbone, G.A. Otterson, D.H. Owen
Journal: Journal of Thoracic Oncology (2024)
P3.08F.03 NRG LU008: Phase III Randomized Trial of Primary Tumor SBRT Followed by Concurrent Mediastinal Chemoradiation for LA-NSCLC
Authors: J. Heinzerling, C. Hu, C.B. Simone, K.F. Mileham, K.A. Higgins, L. Lin, M.E. Abazeed, N. Ohri, J.D. Bradley
Journal: Journal of Thoracic Oncology (2024)
P3.12C.02 MET Fusions in NSCLC: Prevalence, Oncogenicity, and Resistance Mechanism
Authors: S. Nakazawa, F. Pecci, D. Gazgalis, F. Gottlieb, B. Ricciuti, J. Alessi, A. Di Federico, M. Aldea, E. Garbo, M. Gandhi, A. Saini, W. Feng, F. Facchinetti, M. Makarem, D. Haradon, J. Che, M. Awad, P. Jänne
Journal: Journal of Thoracic Oncology (2024)
P3.08F.06 PLATINUM Trial: Preliminary Analysis of Lazertinib Therapy in Locally Advanced, Unresectable, EGFR Mutation(+) NSCLC Following CCRT
Authors: S.Y. Lee, J. Choi, T.W. Jang, S.H. Lee, D.W. Park, S.I. Choi, S.H. Yoon, J.H. Lim, J.E. Lee, S.Y. Lee, S.H. Park, I.-J. Oh, E.Y. Kim, J.C. Lee
Journal: Journal of Thoracic Oncology (2024)
P3.12D.02 Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutated Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)
Authors: S.M. Lim, B.C. Cho, J.Y. Han, S.W. Kim, K.H. Lee, M. Nagasaka, A. Jo, E. Seah, C. Kim, T. Reungwetwattana
Journal: Journal of Thoracic Oncology (2024)
P3.13C.03 Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC
Authors: A. Piedra, A. Guinart-Cuadra, M. Mulet, C. Zamora, J. Alejandre, S. Martínez-Recio, A. Barba, I. Sullivan, J. Serra-López, D. Isla, E. Arriola, L. Paz-Ares, M.P. Diz, A.L. Moreno, Á. Callejo, S. Vidal, M. Majem
Journal: Journal of Thoracic Oncology (2024)
P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
Authors: Q. Zhou, Y. Pan, X.-N. Yang, Q.-T. Yu, W.-H. Zhao, T.-M. Zhang, A.-W. Liu, W.-N. Feng, X.-R. Dong, Y. Yang, M.-F. Zhao, P.-L. Wang, Y. Fan, H. Luo, B.-H. Wang, Y.-S. Shu, Y. Liu, J. Zhao, Q. Bu, J. Li, F. Xu, L.-H. Sun, S.-Y.M. Liu, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
P3.12E.04 Long-Term Outcomes with Sotorasib in KRAS G12c-Mutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436
Authors: S. Novello, N. Maimon, J. Stevenson, W. Petty, C.G. Ferreira, I. Morbeck, A. Zer, J. Bauman, S. Kalmadi, C. Xia, A.R. Meloni, B. Mehta, C. Ardito-Abraham, W. Kormany, M. Awad
Journal: Journal of Thoracic Oncology (2024)
P3.12C.05 Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC
Authors: M. Aldea, E. Garbo, B. Ricciuti, M. Makaram, X. Wang, F. Pecci, A. Saini, F. Paoloni, T. Gorria, J. Connors, M. Awad
Journal: Journal of Thoracic Oncology (2024)
Prescribing strength training for stroke recovery: a systematic review and meta-analysis of randomised controlled trials
Authors: Kenneth S Noguchi, Kevin Moncion, Elise Wiley, Ashley Morgan, Eric Huynh, Guilherme Moraes Balbim, Brad Elliott, Carlene Harris-Blake, Brent Krysa, Barb Koetsier, Karolyn Pinili, Marla K Beauchamp, Stuart M Phillips, Lehana Thabane, Ada Tang
Journal: British Journal of Sports Medicine (2024)

Objective To examine the effects of strength training on patient-important outcomes of stroke recovery and to quantify the influence of the exercise prescription on treatment effects. Design Systematic review and meta-analysis. Data sources Eight electronic databases (MEDLINE, EMBASE, EMCARE, AMED, PsycINFO, CINAHL, SPORTDiscus, and Web of Science) and two clinical trial registries (ClinicalTrials.gov and WHO International Clinical Trials Registry Platform) were searched from inception to 19 June 2024. Eligibility criteria Randomised controlled trials were eligible if they examined the effects of strength training compared with no exercise or usual care and reported at least one exercise prescription parameter. An advisory group of community members with lived experience of stroke helped inform outcomes most relevant to stroke recovery. Results Forty-two randomised trials (N=2204) were included. Overall risk of bias was high across most outcomes. Strength training improved outcomes rated as ‘critical for decision-making’ by the advisory group, including walking capacity (standardised mean difference (SMD)=0.95 (95% CI 0.34–1.56)), balance (SMD=1.13 (0.51–1.75)), functional ability and mobility (SMD=0.61 (0.09–1.14)), and habitual (mean difference (MD)=0.05 m/s (0.02–0.09)) and fast-paced walking speed (MD=0.09 m/s (0.01–0.17)), with very low to moderate certainty of evidence, mainly due to risk of bias and inconsistency. More frequent strength training, traditional strength training programmes and power-focused intensities (ie, emphasis on movement velocity) were positively associated with walking capacity, health-related quality of life and fast-paced walking speed. Conclusion Strength training alone or combined with usual care improves stroke recovery outcomes that are important for decision-making. More frequent strength training, power-focused intensities and traditional programme designs may best support stroke recovery. PROSPERO registration number CRD42023414077.